Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 3
2012 1
2013 10
2014 41
2015 65
2016 90
2017 123
2018 117
2019 100
2020 131
2021 132
2022 130
2023 45
Text availability
Article attribute
Article type
Publication date

Search Results

855 results
Results by year
Filters applied: . Clear all
Page 1
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.
Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, Schrock A, Campbell B, Shlien A, Chmielecki J, Huang F, He Y, Sun J, Tabori U, Kennedy M, Lieber DS, Roels S, White J, Otto GA, Ross JS, Garraway L, Miller VA, Stephens PJ, Frampton GM. Chalmers ZR, et al. Genome Med. 2017 Apr 19;9(1):34. doi: 10.1186/s13073-017-0424-2. Genome Med. 2017. PMID: 28420421 Free PMC article.
Molecular determinants of response to PD-L1 blockade across tumor types.
Banchereau R, Leng N, Zill O, Sokol E, Liu G, Pavlick D, Maund S, Liu LF, Kadel E 3rd, Baldwin N, Jhunjhunwala S, Nickles D, Assaf ZJ, Bower D, Patil N, McCleland M, Shames D, Molinero L, Huseni M, Sanjabi S, Cummings C, Mellman I, Mariathasan S, Hegde P, Powles T. Banchereau R, et al. Nat Commun. 2021 Jun 25;12(1):3969. doi: 10.1038/s41467-021-24112-w. Nat Commun. 2021. PMID: 34172722 Free PMC article. Clinical Trial.
Comprehensive molecular profiling broadens treatment options for breast cancer patients.
Kawaji H, Kubo M, Yamashita N, Yamamoto H, Kai M, Kajihara A, Yamada M, Kurata K, Kaneshiro K, Harada Y, Hayashi S, Shimazaki A, Mori H, Akiyoshi S, Oki E, Oda Y, Baba E, Mori M, Nakamura M. Kawaji H, et al. Cancer Med. 2021 Jan;10(2):529-539. doi: 10.1002/cam4.3619. Epub 2020 Dec 4. Cancer Med. 2021. PMID: 33274848 Free PMC article.
Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database.
Singal G, Miller PG, Agarwala V, Li G, Kaushik G, Backenroth D, Gossai A, Frampton GM, Torres AZ, Lehnert EM, Bourque D, O'Connell C, Bowser B, Caron T, Baydur E, Seidl-Rathkopf K, Ivanov I, Alpha-Cobb G, Guria A, He J, Frank S, Nunnally AC, Bailey M, Jaskiw A, Feuchtbaum D, Nussbaum N, Abernethy AP, Miller VA. Singal G, et al. JAMA. 2019 Apr 9;321(14):1391-1399. doi: 10.1001/jama.2019.3241. JAMA. 2019. PMID: 30964529 Free PMC article.
Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin.
Woodhouse R, Li M, Hughes J, Delfosse D, Skoletsky J, Ma P, Meng W, Dewal N, Milbury C, Clark T, Donahue A, Stover D, Kennedy M, Dacpano-Komansky J, Burns C, Vietz C, Alexander B, Hegde P, Dennis L. Woodhouse R, et al. PLoS One. 2020 Sep 25;15(9):e0237802. doi: 10.1371/journal.pone.0237802. eCollection 2020. PLoS One. 2020. PMID: 32976510 Free PMC article.
Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer.
Sivapiragasam A, Ashok Kumar P, Sokol ES, Albacker LA, Killian JK, Ramkissoon SH, Huang RSP, Severson EA, Brown CA, Danziger N, McGregor K, Ross JS. Sivapiragasam A, et al. Cancer Med. 2021 Jan;10(1):53-61. doi: 10.1002/cam4.3550. Epub 2020 Dec 12. Cancer Med. 2021. PMID: 33314633 Free PMC article.
855 results